Genmab

	29/4 22:43 af Bulder	Men det gjorde Genmab ikke, kan jeg se i arkiverne. Så det bliver nok, når JnJ udsender en meddelelse.
	29/4 22:41 af Bulder	Sidste år reklamerede JnJ for JnJ372. Så det gør de nok også i år.
	29/4 22:34 af Bulder	Men måske overlader de det til JnJ at reklamere
	29/4 22:31 af GeorgeBest	Ja rigtigt
	29/4 22:31 af Bulder	De plejer at opregne revl og krat
	29/4 22:29 af GeorgeBest	Bulder 21:33. Er det ikke ligegyldigt om Genmab fremhæver disse? De er jo med på ASCO.
	29/4 22:22 af Bulder	?
	29/4 22:10 af Solsen	BTD = late breaker
	29/4 22:01 af Bulder	Det kunne måske forklare Teclistamab, men ikke Amivantamab?
	29/4 21:53 af Solsen	Mon ikke JNJ kunne vælge at holde lav profil mht kombinationsmulighederne til dara af konkurrencehensyn. De er i fuld gang med at afprøve (link)
	29/4 21:52 af Bulder	Men dreamm-9 kan der umuligt være data fra. Det er nok bare en præsentation af studiet. Så sent som februar var dreamm-9 kun på planlægningsstadiet.
	29/4 21:45 af Bulder	Og i 1. linje: DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).
	29/4 21:39 af Bulder	GSK's ADC er der også: DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
	29/4 21:37 af Bulder	Nu virker søgemaskinen. Fandt denne her: A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results. Skal satme under observation.
	29/4 21:33 af Bulder	Hvorfor nævner de ikke Teclistamab og Amivantamab? Det er ellers de tunge MM-drenge (og piger) der er med i Teclistamab.
	29/4 21:10 af KWC	Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study - Virtual poster presentation
	29/4 21:10 af KWC	Epcoritamab: Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/ refractory B-NHL: Complete dose escalation data and efficacy results from a phase I/II trial - Virtual poster presentation Tisotumab Vedotin: Phase Ib/II trial of tisotumab vedotin ± bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024) - Virtual poster presentation Daratumumab (Submitted by Janssen Biotech, Inc.): Cort
	29/4 21:09 af KWC	:-)
	29/4 21:08 af GeorgeBest	(link)
	29/4 21:08 af KWC	“Although this year’s ASCO will be a virtual conference due to the difficult and unprecedented circumstances, we are pleased that data on our proprietary pipeline and partnered programs has been accepted for presentation at this prestigious conference. We are particularly looking forward to the data presentation that will demonstrate continued solid progress in our development of epcoritamab (DuoBody-CD3xCD20),” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
	29/4 21:08 af KWC	accepted for presentation at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, taking place from May 29 to 31, 2020. The titles of the abstracts are currently available on the ASCO Meeting Library, with the full abstracts scheduled to be published on May 13, 2020. A list of the abstracts is provided below, and includes one on epcoritamab, one on tisotumab vedotin (Trial in Progress) and four on daratumumab. Beginning Friday, May 29, 2020 at 8:00 AM EDT, poster s
	29/4 21:07 af KWC	Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program Media Release Copenhagen, Denmark, April 29, 2020 Six industry sponsored abstracts regarding Genmab and Genmab partnered programs selected for presentation at ASCO20 Virtual Scientific Program, including data from the epcoritamab (DuoBody®-CD3xCD20) Ph I/II dose-escalation study. Genmab A/S (Nasdaq: GMAB) announced today that six industry sponsored abstracts regarding Genmab and Genmab partnered programs were accept
	29/4 20:41 af Bulder	Yes, or maybe EHA, 2 weeks after asco
	29/4 20:34 af E L	but Sukkeralf also suggested ESMO as alternative, very well possible, late in the year filing?

	29/4 20:33 af E L	to be honest; if it will be now, i think late breaker would be most likely
	29/4 20:31 af Bulder	Come to think about it: These titles do not include late breaking. So still a chance.
	29/4 20:30 af Bulder	I was hoping for Andromeda
	29/4 20:29 af Bulder	Yes, but not before full abstracts are published I think
	29/4 20:28 af E L	Genmab usually sends an email with titles
	29/4 20:27 af E L	so maybe still to come, but doubt that
	29/4 20:27 af E L	ASCO tweet says : Thanks for your patience as #ASCO20 abstract titles are loading into Meeting Library. We'll tweet a link once the website is fully loaded.
	29/4 20:26 af E L	No and no
	29/4 20:20 af Bulder	E L I still cannot make asco's search machine work. You didn't see InnovaTV204? Only 205? And no Andromeda?
	29/4 19:23 af Bulder	Jeg kan ikke få den søgemaskine til at virke. Var der noget om Andromeda?
	29/4 19:23 af Bulder	Gider du ikke poste dem, når du har skrevet dem allesammen ned ;-)
	29/4 19:20 af Solsen	Nu skal jeg til at have noter til alle de vanskelige navne ;-)
	29/4 18:49 af JørgenVarnæs	iPad
	29/4 18:49 af JørgenVarnæs	Nice. Could be grelt Winther another run at the throne in cll
	29/4 18:47 af GeorgeBest	as usual
	29/4 18:47 af GeorgeBest	Thanks E L, så usual you were the fastest :-)
	29/4 18:43 af E L	and 7 results for Dara
	29/4 18:41 af E L	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20...
	29/4 18:41 af E L	Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific...
	29/4 18:39 af E L	Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with...
	29/4 18:38 af E L	Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or...
	29/4 18:34 af E L	ASCO titels up (link)
	29/4 18:13 af GeorgeBest	Webinar (link)
	29/4 17:15 af Sukkeralf	So I guess we will not see anything from that - nice papers but no commercial value
	29/4 17:15 af Sukkeralf	Its seems like Celgene bought Acetylon Pharmaceuticals and outsourced ricolinostat to Regenacy Pharmaceuticals
	29/4 17:08 af E L	;-)